Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Sep 30, 2021 8:27pm
147 Views
Post# 33950512

RE:RE:RE:Current capacity 1000 tests per day

RE:RE:RE:Current capacity 1000 tests per dayI was trying to point out the capacity fo 1000 tests per day.

At $395 per test, that would be $395,000 per day.

And that is just one of the labs. There is another lab for US sample processing.


Obviously we don't know how many tests per day they are doing and when associated revenues will make their way to PMN via the Immusafe JV.  

The revenues will come from this company to PMN via Immusafe

from the COVIDimmunityPassport website (About Us page): BC Neuroimmunology Laboratory focuses on diagnostic testing in neuro-immunological disorders. During this pandemic, the lab has supported the COVID-19 battle by performing PCR testing and, more recently, evaluating post-vaccination antibodies. Immusafe Inc was created to commercialize this test to physicians and their patients.

https://covidimmunitypassport.com/about-us/



<< Previous
Bullboard Posts
Next >>